ARCHIVES

FDA News: FDA Approved A Supplemental New Drug Application For Nexavar Tablets (Sorafenib) For The Treatment Of Patients With Locally Recurrent Or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory To Radioactive Iodine Treatment.

This article is from The Cancer Letter archive.

Vol. 39 No. 45 | December 17, 2013

Download PDF Visit The Full Archive

Related Articles

NCI Takes Action Against Investigators Who Gave Drug Without An IND; M.D. Anderson Contract Canceled

August 28, 1981

DCT Board Gives Concept Approval to “National Drug Discovery Groups,” Suggests Four At $1 Million Each

June 11, 1982

R01 Payline To Increase From 21st to 22nd Percentile; Barcelona Hospital Wins BMS Cancer Research Grant

June 14, 2002

Surgeons Feel Cooperative Groups Discriminate Against Them, Ask For Better Deals From CCIRC

March 11, 1977

Pediatric CCP Controversy Splits Group Leaders; National Consortium Forms; NCAB to Watch Closely

January 14, 1983

DCCR Merit Review Finds some Excellent contract Projects, Some Not So Good; Some Are Terminated

February 25, 1977